



edited by

Ananda M. Chakrabarty

Arsénio M. Fialho

Microbial Infections and Cancer Therapy

Recent Advances



A grayscale electron micrograph showing several cells with prominent, dark, oval nuclei and granular cytoplasm. The cells are arranged in a somewhat regular pattern, with some showing clear cell boundaries. The background is dark and textured, suggesting a dense cellular environment.

Microbial Infections and Cancer Therapy



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Microbial Infections and Cancer Therapy

Recent Advances

edited by

Ananda M. Chakrabarty

Arsénio M. Fialho

PAN STANFORD  PUBLISHING

Published by

Pan Stanford Publishing Pte. Ltd.
Penthouse Level, Suntec Tower 3
8 Temasek Boulevard
Singapore 038988

Email: editorial@panstanford.com

Web: www.panstanford.com

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Microbial Infections and Cancer Therapy: Recent Advances

Copyright © 2019 Pan Stanford Publishing Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4774-86-4 (Hardcover)

ISBN 978-1-351-04190-4 (eBook)

Contents

<i>Preface</i>	xv
1. <i>Bifidobacterium</i> as a Delivery System of Functional Genes for Cancer Therapy	1
<i>Chao Han, Yu-Qing Dai, Zi-Chun Hua, Geng-Feng Fu, Yan Yin, Bi Hu, and Gen-Xing Xu</i>	
1.1 The Potential Superiority of <i>Bifidobacterium</i> as a Delivery System for Cancer Gene Therapy	2
1.1.1 The Biological Features of <i>Bifidobacterium</i> Associated with Cancer Gene Therapy	2
1.1.2 Endogenous Plasmids and Cloning Vectors in <i>Bifidobacterium</i>	3
1.1.3 Expression Plasmids in <i>Bifidobacterium</i> for Cancer Gene Therapy	5
1.1.3.1 Plasmid pBLES100	5
1.1.3.2 Plasmid pGEX-1LamdaT	6
1.1.3.3 Plasmids pBV220 and pBV22210	6
1.2 The Anticancer Mechanism of <i>Bifidobacterium</i> as an Oral Delivery System for Cancer Gene Therapy	10
1.2.1 Oral Administration of <i>Bifidobacterium</i> Affects the Immune System	10
1.2.2 Oral Administration of <i>Bifidobacterium</i> Modulates Gut Microbial Community	10
1.2.3 Oral Administration of <i>Bifidobacterium</i> Affects Cancer Cell Signal Transduction	11
1.3 The Application of <i>Bifidobacterium</i> as a Delivery System of Functional Genes for Cancer Therapy	11
1.3.1 <i>Bifidobacterium</i> as a Delivery System of Functional Genes for Cancer Gene Therapy	11

1.3.2	<i>Bifidobacterium</i> Combination with Other Factors for Synergy	15
1.3.2.1	Combination with radiation and chemotherapeutic drugs	15
1.3.2.2	Combination with prebiotics	18
1.3.2.3	Combination with trace element selenium	19
1.3.3	The New Mutagenesis Strategies for Genetic Modification of <i>Bifidobacterium</i>	20
1.3.3.1	Single-crossover plasmid insertion	21
1.3.3.2	Double-crossover and double-crossover markerless gene deletion	21
1.3.3.3	Homologous recombination mediated by a temperature-sensitive plasmid	22
1.4	Future Prospects	22
2.	Therapy with Oncolytic <i>Clostridium novyi</i>-NT: From Mice to Men	33
	<i>Shibin Zhou</i>	
2.1	Targeted Therapies at the Tissue Level	33
2.2	Clostridia as Live Therapeutic Agents for Cancer Therapy	35
2.3	<i>C. novyi</i> -NT as a Live Therapeutic Agent for Cancer Therapy	37
2.3.1	<i>C. novyi</i>	37
2.3.2	<i>C. novyi</i> -NT	38
2.4	Preclinical Studies: Toxicity Associated with <i>C. novyi</i> -NT Treatment	44
2.5	Preclinical Studies: Therapeutic Effects	46
2.6	Preclinical Studies: Combination Approaches for Optimized Efficacy	50
2.7	From Bench to Bedside	53
2.8	Clinical Studies: Canine Trial	55
2.9	Clinical Studies: Phase I Human Trial	57
2.10	Summary and Future Perspectives	58

3. Genetic Engineering of Clostridial Strains for Cancer Therapy 73

Maria Zygouropoulou, Aleksandra Kubiak, Adam V. Patterson, and Nigel P. Minton

3.1	Tumor Hypoxia and Necrosis: A Blessing in Disguise?	74
3.2	Clostridia as Cancer-Fighting Agents	75
3.2.1	Embodiment of Treatment	76
3.2.1.1	Administration route and form	76
3.2.1.2	Tumor colonization	76
3.2.1.3	Mechanism of action	77
3.2.1.4	Termination of treatment	77
3.2.2	Limitations of Clostridial Oncolysis	78
3.3	Genetic Engineering Approaches	79
3.3.1	The Underpinning Science	83
3.3.1.1	Genetic tools	83
3.3.1.2	Strain selection	86
3.3.2	Clostridial-Directed Enzyme Prodrug Therapy	88
3.3.2.1	Cytosine deaminase	90
3.3.2.2	Nitroreductases	91
3.3.2.3	Carboxypeptidase G2	96
3.3.3	Clostridial-Directed Antibody Therapy	97
3.3.3.1	Anti-hypoxia-inducible factor 1 alpha antibody	97
3.3.3.2	Antivascular endothelial growth factor antibody	98
3.3.4	Immunotherapy	99
3.3.4.1	Tumor necrosis factor alpha	100
3.3.4.2	Interleukin-2	101
3.3.4.3	Interleukin-12	102
3.3.5	Various Functionalities	103
3.3.5.1	Colicin E3	103
3.3.5.2	Methionine- γ -lyase	103
3.3.5.3	Panton Valentine Leukocidin	104
3.3.6	Imaging	105

3.4	Conclusion and Future Opportunities	109
4.	Bacteria-Derived Alternatives to Live <i>Mycobacterium bovis</i> Bacillus Calmette–Guerin for Nonmuscle Invasive Bladder Cancer Treatment	123
	<i>Esther Julián and Estela Noguera-Ortega</i>	
4.1	Success of BCG in Bladder Cancer Treatment	124
4.2	Problems Associated with the Intravesical Instillation of BCG	125
4.3	Alternatives to Viable BCG	126
4.3.1	Bacteria Other Than Mycobacteria	127
4.3.1.1	Live bacteria	131
4.3.1.2	<i>Salmonella</i>	131
4.3.1.3	<i>Corynebacterium</i>	131
4.3.1.4	Lactic bacteria	132
4.3.1.5	Local administration to the tumor	132
4.3.1.6	Oral administration	133
4.3.2	Bacterial Toxins	134
4.3.2.1	Lipid A from <i>Salmonella</i>	134
4.3.2.2	<i>Helicobacter</i> toxins	134
4.3.2.3	<i>Staphylococcus aureus</i> toxins	134
4.3.2.4	<i>Clostridium endotoxin</i>	135
4.3.2.5	<i>Pseudomonas</i> toxin	135
4.3.2.6	<i>Streptococcus</i>	136
4.3.3	Other Mycobacteria and/or Mycobacterial Components	136
4.3.3.1	The peculiarities of mycobacteria	136
4.3.3.2	Mycobacteria antigens and cell extracts	139
4.3.3.3	Whole nonviable mycobacteria	145
4.3.3.4	Live nontuberculous mycobacteria	150
4.3.3.5	Future contributions of mycobacteria to BC treatment	156
4.4	Future Perspectives	159

5. Genetically Modified *Salmonella* as Cancer Therapeutics: Mechanisms, Advances, and Challenges 189

Xiaoxin Zhang and Zi-Chun Hua

5.1	Introduction	190
5.2	Mechanisms of Tumor Suppression	191
5.2.1	Host Immunity and <i>Salmonella</i>	191
5.2.1.1	Innate immunity and <i>Salmonella</i>	191
5.2.1.2	Adaptive immunity and <i>Salmonella</i>	192
5.2.2	The Traits of <i>Salmonella</i> Required for Cancer Therapy	192
5.3	Optimization of <i>Salmonella</i> -Mediated Delivery Systems	193
5.3.1	Optimization of Bacterial Vectors	194
5.3.1.1	Attenuation of <i>Salmonella</i> vectors	194
5.3.1.2	Screen of tumor-specific <i>Salmonella</i>	195
5.3.1.3	Attenuation versus immunogenicity	196
5.3.2	Genetic Stability of Expression of Heterologous Genes	196
5.3.3	Regulation of Therapeutic Protein Expression	198
5.3.4	Compartmentalization of Therapeutic Agents	199
5.3.4.1	Direct surface display	200
5.3.4.2	The export of heterologous proteins to extracellular space	200
5.3.4.3	The cell lysis system	201
5.3.5	Expression of Anticancer Agents and Modulation of the Tumor Microenvironment	202
5.4	Combined Therapy	204
5.4.1	Combined with Chemotherapy	204
5.4.2	Combined with Other Treatments	205
5.5	Conclusion	206

6. Genetically Engineered Oncolytic <i>Salmonella typhimurium</i>	221
<i>Jin Hai Zheng and Jung-Joon Min</i>	
6.1 Introduction	222
6.1.1 Bacterial Cancer Therapy	222
6.1.2 Δ ppGpp <i>S. typhimurium</i> Strain and Cancer Therapy	223
6.1.3 Strategies for Enhanced Bacterial Cancer Therapy	223
6.2 Generation of Attenuated Strains and Molecular Imaging Strategies	224
6.2.1 Engineering of <i>S. typhimurium</i> Strains for Virulence Attenuation	224
6.2.2 Expression of Reporter Genes for Noninvasive Imaging	225
6.3 Surface Engineering for Enhanced Tumor Targeting	226
6.4 Engineering of <i>Salmonella</i> for Payload Expression	227
6.4.1 Inducible Expression System	227
6.4.1.1 Tetracycline/doxycycline-inducible pTet promoter	228
6.4.1.2 L-arabinose-inducible pBAD promoter	229
6.4.1.3 Strategy to enhance pBAD promoter performance with Ara mutant	230
6.4.2 Strategy to Enhance Plasmid Maintenance in Bacteria	231
6.4.3 Payloads for <i>Salmonella</i> -Mediated Cancer Therapy	231
6.4.3.1 Cytotoxic protein: ClyA	232
6.4.3.2 Immunomodulator: FlaB	233
6.4.3.3 Mitochondrial target domain: Noxa	236
6.4.3.4 Apoptotic cell death inducer: L-asparaginase	237
6.4.3.5 Immunotoxin: TGF α -PE38	238

6.5	Stimulation of Host Immunity	238
6.5.1	Activation of the Inflammasome Pathway	238
6.5.2	Macrophage Polarization	239
6.6	Application in Diseases	241
6.6.1	Cancer Therapy	241
6.6.2	Myocardial Infarction and Other Diseases	242
6.7	Summary	244
7.	Engineering <i>Escherichia coli</i> to Combat Cancer	253
	<i>Carlos Piñero-Lambea, David Ruano-Gallego, Gustavo Bodelón, Beatriz Álvarez, and Luis Ángel Fernández</i>	
7.1	Introduction	254
7.1.1	Bacterial Therapies against Cancer	254
7.1.2	Hypoxic Tumor Microenvironment and Bacterial Colonization	256
7.2	<i>Escherichia coli</i> as an Anticancer Agent	257
7.2.1	Tumor Colonization by <i>E. coli</i>	257
7.2.2	Genetic Engineering <i>E. coli</i> for Tumor Therapy and Diagnosis	258
7.3	Synthetic Biology of <i>E. coli</i> to Combat Cancer	260
7.3.1	Synthetic Biology and the Design of Bacteria against Tumors	260
7.3.2	Synthetic Adhesins to Program the Adhesion of <i>E. coli</i>	261
7.3.3	Synthetic Adhesins Improve <i>E. coli</i> Tumor Targeting	264
7.3.4	Selection of Synthetic Adhesins against Cell Surface Antigens	268
7.3.5	Arming Engineered <i>E. coli</i> with Protein Injection Nanosyringes	269
7.3.6	Constructing SIEC Bacteria	271
7.3.7	SIEC Bacteria Assembles Functional Injectisomes	274
7.3.8	SIEC Bacteria Translocate Proteins to Tumor Cells	276
7.4	Conclusions and Future Perspectives	278

8. Live <i>P. aeruginosa</i> as a Cancer Vaccine Vector	291
<i>Y. Wang, B. Polack, and B. Toussaint</i>	
8.1 Introduction	291
8.2 How to Make a <i>P. aeruginosa</i> Strain a Powerful Tool for Protein Delivery	293
8.2.1 <i>P. aeruginosa</i> 's T3SS Is Able to Secrete an Active Bacterial-Human Hybrid Protein Using T3SS	294
8.2.2 The Secreted Hybrid Protein Is Active in a Human Cell Line	295
8.2.3 Detoxification of <i>P. aeruginosa</i> : An Iterative Gene Knockout Method	295
8.2.4 A Remote Control for <i>P. aeruginosa</i>	296
8.2.5 Determination of the Optimal T3SS Secretion Sequence for Hybrid Proteins	297
8.3 Proof of Concept of Active and Specific Immunotherapy by <i>P. aeruginosa</i> T3SS	299
8.3.1 <i>Ex Vivo</i> Experiments	300
8.3.2 Vaccinal and Therapeutic Efficiency of BacVac in a Mouse Model of Melanoma	301
8.4 Optimization of T3SS-Based Bacterial Vector for Clinical Use	302
8.4.1 Bi-antigen Delivery Pattern Design	302
8.4.2 Virulence Attenuation	305
8.4.3 Chemically Defined Growth Medium	306
8.4.4 Optimization of Vaccination Scheme and Vaccination Mode	307
8.4.5 Design of the Killed but Metabolically Active Procedure	309
8.4.5.1 Comparison of the immune response induced by live attenuated bacteria and KBMA bacteria	311
8.5 Conclusion	313

9. The Anticancer Potential of the Bacterial Protein Azurin and Its Derived Peptide p28 **319**

Ana Rita Garizo, Nuno Bernardes, Ananda M. Chakrabarty, and Arsénio M. Fialho

9.1	Introduction	320
9.2	Bacterial Protein Azurin	321
9.3	Entry Mechanism of Azurin/p28 into Human Cells and Subsequent Effects	323
9.4	Azurin Mode of Action in the Levels of Cadherin Proteins	325
9.5	Interaction between Azurin/p28 and Surface Receptors in Cancer Cells and Other Activities	328
9.6	Azurin/p28 Application in the Treatment of Cancer	329
9.7	Effects of Azurin/p28 Treatment in Combination with Drugs on Cancer Cells	331
9.8	Conclusions	333

10. Prospective Therapeutic Applications of Bacteriocins as Anticancer Agents **339**

Lígia F. Coelho, Nuno Bernardes, and Arsénio M. Fialho

10.1	Introduction	340
10.2	Bacteriocins, from Antimicrobial to Anticancer Agents	340
10.3	ACPs as a Selective Oncolytic Therapy	342
10.4	Classification of Bacteriocins	344
10.5	Action against Cancer Cells	350
	10.5.1 Class I: Lantibiotics and Lasso Peptides	352
	10.5.2 Class II: Microcin, Pediocins, and Plantaricin A	356
	10.5.3 Class III: Anticancer Proteins	357
10.6	Clinical Applications and Patents	358
10.7	Future Perspectives of Bacteriocins as Anticancer Agents	359

11. Bacteriocins as Anticancer Peptides: A Biophysical Approach	367
<i>Filipa D. Oliveira, Miguel A.R.B. Castanho, and Diana Gaspar</i>	
11.1 Introduction	368
11.2 Antimicrobial Peptides with Anticancer Activity: An Innovative Anticancer Treatment	370
11.3 Bacteria as a Source of Anticancer Peptides: Bacteriocins	372
11.4 Biophysical Techniques: A Key to Unravelling Bacteriocins' Modes of Action	378
11.4.1 Cellular Viability: Metabolic Dyes	383
11.4.2 Flow Cytometry	385
11.4.3 Microscopy Techniques	388
11.4.4 Fluorescence Spectroscopy	392
11.4.5 Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy	393
11.5 Final Remarks	396
12. Where Cancer and Bacteria Meet	411
<i>Alexandra Merlos, Ricardo Perez-Tomás, José López-López, and Miguel Viñas</i>	
12.1 Introduction	411
12.2 Infection and Neoplasia	412
12.2.1 Gram-Negative Bacteria	414
12.2.2 Gram-Positive Bacteria	417
12.3 Head and Neck Cancers and Bacterial Oral Microbiota	418
12.4 Bacteria and Bacterial Products in Cancer Treatment	422
12.4.1 Prodiginines	423
12.4.1.1 Properties and mechanism of action of prodigiosin	424
12.4.2 Tambjamines	426
12.4.2.1 Properties and mechanism of action	427
12.4.2.2 Synthetic analogs of tambjamines	427
<i>Index</i>	437

Preface

The bacterial world is extremely diversified, evidencing the existence of bacteria able to successfully colonize the most varied environments, that is, from inhospitable places on the planet to their coexistence with humans. Such nature is based on the existence of unique and complex genetic systems, which is seen to be the key for the great success of their ubiquity. Nowadays, microbial biotechnology makes use of live microorganisms or derived products to find various industrial applications, particularly in health, food, and environment. Among those, in recent years, the use of pathogenic (attenuated) or non-pathogenic live bacteria and their purified products as new anticancer agents have gained prominence. In fact, based on a significant number of scientific publications, human clinical trials, and even clinical practice, it is found that bacteria can be successfully used as agents capable of stimulating the immune system and fight cancer. Furthermore, through genetic intervention, it is possible to modify bacteria and use them as gene delivery vehicles for anticancer proposals. In addition, it also deserves mentioning the fact that bacteria harboring this additional genetic information are able to show tropism, preferentially colonizing the tumor microenvironment. Besides live bacteria, the use of purified bacterial products as anticancer agents, namely proteins, peptides, and compounds derived from secondary metabolism, has also gained relevance. In this book, twelve chapters address the most recent developments regarding the success and limitations of the use of bacteria and their products as cancer therapeutic agents. Considering that we now face an era where the resistance of cancer cells to chemotherapy has become a global burden, the establishment of alternative anticancer therapies may add value in the definition of more efficient therapeutic protocols. As editors, we hope to be able to bring together in this book the most relevant and up-to-date information on this subject.

Ananda M. Chakrabarty

Arsénio M. Fialho

Autumn 2018



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Chapter 1

***Bifidobacterium* as a Delivery System of Functional Genes for Cancer Therapy**

Chao Han,^a Yu-Qing Dai,^b Zi-Chun Hua,^a Geng-Feng Fu,^c Yan Yin,^a Bi Hu,^a and Gen-Xing Xu^a

^a*The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science, Nanjing University, Nanjing 210046, China*

^b*College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210029, China*
^c*Jiangsu Provincial Center for Disease Prevention and Control, Nanjing, China*

genxingxu@nju.edu.cn

Bifidobacteria were first discovered in 1899 by Henri Tissier, a French pediatrician at the Pasteur Institute in Paris. They are gram-positive, anaerobic, catalase-negative, fermentative rods, which are often Y- or V-shaped. As an anaerobe, *Bifidobacteria* can germinate and proliferate in the hypoxic regions of solid tumors. Plasmids of *Bifidobacterium* encode many specific characteristics of *Bifidobacterium*, and they can also establish shuttle vectors to express exogenous genes. Previous studies exhibited anticancer effects of *Bifidobacteria* on many kinds of tumors. To date, only a few plasmids were found to replicate and express exogenous proteins in *Bifidobacterium*; besides the transformation efficiency and expression level were low in all cases. It can be foreseen that the *Bifidobacterium* will be the most important and perfect vector

Microbial Infections and Cancer Therapy: Recent Advances

Edited by Ananda M. Chakrabarty and Arsénio M. Fialho

Copyright © 2019 Pan Stanford Publishing Pte. Ltd.

ISBN 978-981-4774-86-4 (Hardcover), 978-1-351-04190-4 (eBook)

www.panstanford.com

of anticancer gene in cancer gene therapy. The study on related plasmids of *Bifidobacterium* expression plasmids in *Bifidobacterium* for cancer gene therapy is summarized in this chapter, and the advantages and disadvantages of the use of *Bifidobacterium* as a delivery system of functional genes for cancer gene therapy are also discussed.

1.1 The Potential Superiority of *Bifidobacterium* as a Delivery System for Cancer Gene Therapy

1.1.1 The Biological Features of *Bifidobacterium* Associated with Cancer Gene Therapy

As a delivery system and compared with other bacterial genera, *Bifidobacterium* represents a promising biological tool for cancer therapy. *Bifidobacterium* is gram-positive, a strictly anaerobic bacterium with bifid morphology. Its anaerobic specialty is important for cancer therapy. Tissue oxygen electrode measurements taken in cancer patients show a median range of oxygen partial pressure of 10–30 mm Hg in tumors, with a significant proportion of readings below 2.5 mm Hg, whereas those in normal tissues range from 24 to 66 mm Hg [1]. Early in 1980, Kimura and colleagues showed that genus *Bifidobacterium* could germinate and grow in the hypoxic regions of solid tumors after intravenous injection. Contrastingly, the number of *Bifidobacterium* in normal tissues decreased and then disappeared [2]. Later, Yazawa *et al.* showed that wild-type and genetically engineered *B. longum* has the tumor specificity to localize and germinate in tumor regions [3]. Besides its anaerobic specialty, *Bifidobacterium* is known as a health-promoting and probiotic agent, playing an important role in the maintenance of a proper balance of normal intestinal flora [4]. Some bifidobacterial species are frequently used as the probiotic element in many functional foods, which means a high safety in administration. In early studies, *Bifidobacterium* itself also indicated the effect of cancer prevention [5, 6]. Jagveer *et al.* found that oral administration of *B. longum* exerted strong

antitumor activity, as showed by modulation of the intermediate biomarkers of colon cancer, and reduced tumor outcome [7].

1.1.2 Endogenous Plasmids and Cloning Vectors in *Bifidobacterium*

To develop a cloning vector of *Bifidobacterium*, a comprehensive understanding of the replication mechanism and characterization of natural bifidobacterial plasmids is necessary. Plasmids in *Bifidobacterium* attracted great interest because they encode many special characters and play an important role in the research on genetics and construction of engineering strains for *Bifidobacterium*. *Bifidobacterium* with related plasmids not only revealed its own characteristics but also gained characters encoded by the plasmids, such as lactose catabolism, generation of bacteriocin, drug resistance and antibiotic resistance [8–10].

The majority of bifidobacterial strains do not harbor any plasmid. But if they do, they rarely contain more than one, which range in size from 1 to 19 kb [11]. Several plasmids have been isolated from 9 of the 32 species and 44 plasmids have been fully sequenced and annotated (Table 1.1). The majority of the sequenced plasmids were isolated from *B. longum*. Other sources are *B. asteroides*, *B. bifidum*, *B. breve*, *B. catenulatum*, *B. kashiwanohense*, *B. pseudocatenulatum*, *B. pseudolongum* subsp. *globosum* and *B. sp. A 24* (Table 1.1). Analysis of their replication (Rep) proteins has indicated that the majority of identifying bifidobacterial plasmids replicate by means of the so-called rolling circle mechanism (RCR), while other functions if encoded, remain to a large degree unknown [11, 12].

Several cloning vectors have been constructed with plasmids from *Bifidobacterium* and *Escherichia coli* and transformed into both of them by electroporation. In all cases, electroporation efficiency in *Bifidobacterium* was very low, and numerous attempts have been made to optimize it.

The nucleotide sequence of the *B. longum* B2577 cryptic plasmid pMB1 was sequenced in 1996. Recombinant plasmids containing the pMB1 replicon could replicate in *B. animalis* MB209 [13]. Later, another pMB1-based vector pNC7 was successfully transformed into 10 bifidobacterial species [14]. In 1999, plasmid

pKJ50 was isolated from *B. longum* KJ and a shuttle vector constructed by cloning pKJ50 and a chloramphenicol resistance gene into pBR322 [15].

Table 1.1 Completely sequenced plasmids found in *Bifidobacterium* species

Species	Plasmid	Size (bp)	Accession no.
<i>B. asteroides</i>	pCIBA089	2,111	NC_010908.1
<i>B. bifidum</i>	pB80	4,898	NC_011332.1
<i>B. breve</i>	pCIBb1	5,750	NC_002133.1
	pB21a	5,206	NC_010930.1
	pMP7017	190,178	GI:704484592
	pBR3	4,891	NZ_CP010414.1
<i>B. catenulatum</i>	pBC1	2,540	NC_007068.1
<i>B. kashiwanohense</i>	pBBKW-1	7,716	NC_021875.1
	pBBKW-2	2,920	NC_021876.1
<i>B. longum</i>	pKJ36	3,625	NC_002635.1
	pB44	3,624	NC_004443.1
	pNAC3	10,224	NC_004768.1
	PNAC2	3,684	NC_004769.1
	pNAC1	3,538	NC_004770.1
	pKJ50	4,960	NC_004978.1
	pMG1	3,682	NC_006997.1
	pTB6	3,624	NC_006843.1
	pBIF10	9,275	GI:73665544
	pFI2576	2,197	NC_011139.1
	p6043A	4,896	NC_010857.1
	p6043B	3,680	NC_010861.1
	pSP02	4,896	NC_019200.1
	pNAL8M	4,910	NC_025161.1
	pNAL8L	3,489	NC_025162.1
	pRY68	2,638	NZ_CP010454.1
pDOJH10L	10,073	NC_004252.1	
pDOJH10S	3,661	NC_004253.1	
pBL01	3,626	NC_004943.1	

	p157F-NC1	4,895	NC_015053.1
	p157F-NC2	3,624	NC_015066.1
	p1-5B2	3,624	GI:822874551
	p1-5B1	3,919	GI:822874554
	p1-6B2	3,624	GI:822874529
	p1-6B1	3,919	GI:822874532
	p17-1B	3,919	GI:822874562
	p2-2B	3,624	GI:822874523
	p35B	3,624	GI:822874526
	p72B	3,624	GI:822874548
	pEK13	7,050	GI:822874540
	BLNIAS_P1	4,233	NC_017220.1
	BLNIAS_P2	6,230	NC_017222.1
<i>B. pseudocatenulatum</i>	p4M	4,488	NC_003527.1
<i>B. pseudolongum</i> <i>subsp. Globosum</i>	pASV479	4,815	NC_010877.1
<i>B. sp. A24</i>	pBIFA24	4,892	NC_010164.1

Most *Bifidobacterium* are resistant to a wide range of antibiotics, including vancomycin, gentamicin, kanamycin, streptomycin and nalidixic acid [16]. The used selection markers in *Bifidobacterium* are genes conferring resistance to spectinomycin, erythromycin, chloramphenicol, or ampicillin [17–19].

1.1.3 Expression Plasmids in *Bifidobacterium* for Cancer Gene Therapy

Based on the research of the endogenous plasmids and cloning vectors in *Bifidobacterium*, many shuttle vectors encoding target genes were constructed. Efforts are focused mainly on the following three representatives: *B. longum*, *B. infantis*, and *B. adolescentis* [20]. The main expression plasmids used in *Bifidobacterium* for cancer gene therapy are discussed in the following text.

1.1.3.1 Plasmid pBLES100

pBLES100, which was constructed by cloning with a *B. longum* plasmid, pTB6, and an *E. coli* vector, pBR322, has been used as an

expression vector for several genes in cancer gene therapy. Yazawa *et al.* cloned a gene-encoding spectinomycin adenylyltransferase AAD and the pBLES100 constructs were transferred directly into *B. longum*105-A or 108-A by electroporation. When these genetically engineered *Bifidobacterium* were introduced into tumor-bearing mice, bacteria were found only in the tumor environments [1]. Later, transformed *B. longum*105-A carrying pBLES100-AAD was also used in the gene therapy of chemically induced 7,12-dimethylbenz[a]anthracene (DMBA) rat mammary tumors. Consistent results were obtained demonstrating that transformed *B. longum* selectively colonize the tumors [2, 3].

In another study, Nakamura and colleagues constructed the plasmid pBLES100-S-eCD, which included the HU gene promoter and the gene encoding the cytosine deaminase from *E. coli* (converts the prodrug 5-fluorocytosine (5-FC) to the drug 5-fluorouracil (5-FU)). The results obtained suggest that the *B. longum* plasmid is an excellent gene delivery system and an effective candidate for enzyme/prodrug therapy [21, 22].

1.1.3.2 Plasmid pGEX-1LamdaT

Yi *et al.* successfully constructed a *B. infantis*/CD targeting the gene therapy system with a recombinant CD/pGEX-1LamdaT plasmid [23]. Experiments on the mice melanoma model showed that the tumor volume was significantly inhibited compared with controls after treatment with a combination of transfected *B. infantis* and 5-FC [24]. The engineered *B. infantis* containing the Herpes simplex virus—thymidine kinase (HSV-TK) gene was constructed by transformation of recombinant plasmid PGEX-1LamdaT [25]. Using the rat model of bladder tumors, Xiao *et al.* found that the rats treated with BI-TK/GCV group enhanced the efficacy of tumor growth compared with the normal saline control group [26]. Later, Zhou *et al.* demonstrated the efficacy and safety of the TK/GCV system for cancer therapy by intravenous administration [27].

1.1.3.3 Plasmids pBV220 and pBV22210

In our laboratory, a shuttle pBV220 was used to construct pBV220-endostatin and transformed the recombinant plasmid into *B. adolescentis* and *B. longum*. *B. adolescentis* with endostatin gene

was injected into the mice bearing Heps liver cancer. After determination of the expression of endostatin, the distribution and antitumor effect of transfected *B. adolescentis* were examined. At 168 hours after the third injection of *B. adolescentis* with endostatin gene, *B. adolescentis* cells were only found in the tumor tissues (Fig. 1.1). Our research group utilized a strain of *B. longum* as a delivery system to transport an endostatin gene that can inhibit growth of a tumor. The *B. longum* strain with the endostatin gene (*B. longum*-endostatin) was taken orally by tumor-bearing nude mice through drencher preparation. The results showed that *B. longum*-endostatin could strongly inhibit the growth of solid liver tumor in nude mice and prolong the survival time of such tumor-bearing mice. Furthermore, tumor growth was inhibited more efficiently when the *B. longum*-endostatin treatment included selenium (*Se-B. longum*-En) (Fig. 1.2). *Se-B. longum*-En also could improve the activities of NK and T cells and stimulate the activity of IL-2 and TNF- α in BALB/c mice [20]. Xu *et al.* constructed a new vector pBV22210-endostatin combining a chloramphenicol resistance gene and a cryptic plasmid pMB1 from a wild type *B. longum* strain, and *B. longum*-pBV22210-endostatin exhibited higher stability and stronger inhibitory effect on H22 liver tumor growth in xenografts models than the *B. longum*-pBV220-endostatin. Our results also indicated that the plasmid electroporated into *B. longum* was maintained stable in the absence of selective antibiotics and did not significantly affect biological characteristics of *B. longum*. These results suggested that pBV22210 may be a stable vector in *B. longum* for transporting anticancer genes in cancer gene therapy [28]. Besides the above, other genes were also successfully expressed by shuttle vectors in *Bifidobacterium*.

In addition, Cronin *et al.* constructed a reporter vector pLuxMC1, which is based on the plasmid pBC1 and the *luxABCDE* operon from pPL2lux. Later, they found it stably replicated in *B. breve* UCC2003. Thus, it can track the colonization potential and persistence of this probiotic species in real time [29]. Further studies showed that the *B. breve* harboring the plasmid expressing lux fed to mice bearing tumors were readily detected specifically in tumors, by live whole-body imaging, at levels equal to administration. The reporter gene expression was visible for at least two weeks in tumors [30]. Recently, this team revealed

the evidence, which furthermore underlined the significance of bioluminescent imaging and micro-computed tomography as tools to advance the application of vectors [31].




Figure 1.1 Comparison of the number of *B. adolescentis* carrying pBV220/endostatin plasmid in both tumors and normal tissues, after 68 hours of the third administration of 1×10^8 viable bacilli into tumor-bearing mice through tail vein for each time. After 72 hours of anaerobic cultivation, many colonies of *B. adolescentis* carrying pBV220/endostatin plasmid were observed in the tumor, but no colonies were found in normal tissues. Adapted from Ref. [52].

In another report, Guglielmetti *et al.* transformed the human intestinal bacterium *B. longum* with a vector (pGBL8b) containing the insect luciferase gene. The bioluminescent *B. longum* was used to test the efficacy of different carbohydrates to preserve cell physiology under acidic conditions. The results showed that bioluminescent *B. longum* harboring the pGBL8b plasmid is a valuable tool to study the physiological state of anaerobic bacterial cells under different environmental conditions [32].

Many studies have successfully constructed expression plasmids in *Bifidobacterium*, including those not for anticancer [33, 34]. But the accumulating evidence indicates the stability and expression level of these shuttle vectors, and the vectors were useful for further research and application of *Bifidobacterium* in cancer gene therapy.